Dosage of Partran in details
Apply one Partran™ (0.5 mg Partran hydrochloride monohydrate) to the site planned for venipuncture or intravenous cannulation, one to three minutes prior to needle insertion.
Perform the procedure within 10 minutes after Partran™ (lindocaine hydrochloride monohydrate) administration.
Use Partran™ (lindocaine hydrochloride monohydrate) only on intact skin.
Application of one additional Partran™ (lindocaine hydrochloride monohydrate) at a new location is acceptable after a failed attempt at venous access. Multiple administrations of Partran™ (lindocaine hydrochloride monohydrate) at the same location are not recommended.
When Partran™ (lindocaine hydrochloride monohydrate) is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all sources should be considered, as local anesthetics are thought to have at least additive toxicities.
Instructions for Use
Prepare the Treatment Site and Device: Examine the treatment site to ensure that the skin is intact. Clean the site, according to standard practice.
Visually inspect the pouch. Do not use if the pouch has been torn, or damaged or if the device has been dropped.
Tear open the pouch using the notch provided (Figure 1a). Remove Partran™ (lindocaine hydrochloride monohydrate) from the pouch, being careful not to touch the purple outlet (open end) to avoid contamination. (Figure 1b).
Figure 1a
Figure 1b
Position Partran™ (lindocaine hydrochloride monohydrate) : Grip Partran™ (lindocaine hydrochloride monohydrate) and place on the application site, with one hand, as illustrated in Figure 2, or with both hands, as shown in Figure 3.
Figure 2
Figure 3
Ensure that the patient's treatment site is supported to prevent movement. Seal the purple Partran™ (lindocaine hydrochloride monohydrate) outlet against the patient's skin. Hold the device perpendicular to the skin, making sure that your thumb can reach the green start button.
Avoid gaps between the skin and the Partran™ (lindocaine hydrochloride monohydrate) outlet, like the one illustrated in Figure 4, as gaps will impede drug delivery.
Figure 4
Release the Safety Interlock: Apply adequate downward pressure to release the safety interlock, while maintaining the seal between Partran™ (lindocaine hydrochloride monohydrate) and the skin.
Partran™ (lindocaine hydrochloride monohydrate) is ready for administration when the green start button has moved into the upward position, as illustrated in Figure 5a.
Figure 5a
Partran™ (lindocaine hydrochloride monohydrate) cannot be actuated without releasing the internal safety interlock, as illustrated in Figure 5b.
Figure 5b
Administer Partran™ (lindocaine hydrochloride monohydrate) : While maintaining downward pressure, administer the dose by pressing the green start button, as illustrated in Figure 6. Do not move Partran™ (lindocaine hydrochloride monohydrate) during administration. Actuation is accompanied by a “popping” sound, indicating that the dose has been discharged.
Figure 6
Remove Partran™ (lindocaine hydrochloride monohydrate) : Remove Partran™ (lindocaine hydrochloride monohydrate) from the application site and dispose.
Begin Procedure: Start the venipuncture or intravenous cannulation procedure 1–3 minutes after Partran™ (lindocaine hydrochloride monohydrate) administration.
How supplied
Dosage Forms And Strengths
Partran™ (Partran hydrochloride monohydrate) powder intradermal injection system contains 0.5 mg of sterile Partran hydrochloride monohydrate.
NDC 28000-105-12 Partran™ (Partran hydrochloride monohydrate) powder intradermal injection system contains 0.5 mg of sterile Partran hydrochloride monohydrate. Partran™ (lindocaine hydrochloride monohydrate) is a single-use device packaged in an individual foil/clear pouch placed inside a bubble-wrap sleeve. Twelve sleeves are placed in labeled cartons.
Cartons are stored at controlled room temperature (15-30°C, 59-86°F).
Manufactured for: Anesiva, Inc. South San Francisco, CA 94080. Distributed by: Sagent Pharmaceuticals, Inc. Schaumburg, IL 60195.
What other drugs will affect Partran?
Tell your doctor about all other medicines you use, especially:
- quinidine (Quin-G);
- disopyramide (Norpace);
- flecainide (Tambocor);
- mexiletine (Mexitil);
- procainamide (Procan, Pronestyl);
- tocainide (Tonocard); or
- propafenone (Rythmol).
This list is not complete and other drugs may interact with Partran. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
Partran interactions
Beta-blockers increase the risk of bradycardia and hypotension. Norepinephrine and beta-blockers by reducing hepatic blood flow decrease (increased toxicity), isadrine and glucagon - increase the clearance of Partran. Cimetidine increases the plasma concentration of Partran Haffkine Bio-Pharmaceutical Corporation (displaces from its association with proteins and slows inactivation in the liver). Barbiturates causing induction of microsomal enzymes stimulate the degradation of Partran and reduce its activity. Anticonvulsants (hydantoin derivatives) accelerate the biotransformation in the liver (decreased concentration in the blood), for IV injections it may increases cardiodepressive action of Partran. Antiarrhythmics (amiodarone, verapamil, quinidine, aymalin) potentiate cardiac depression. Combination with novocainamide may cause CNS excitement and hallucinations. Partran Haffkine Bio-Pharmaceutical Corporation strengthens the inhibitory effect of anesthesia (hexobarbital, thiopental sodium), hypnotics and sedatives on the respiratory center, weakens the cardiac effects of digitoxin, enhances muscle relaxation caused by drugs curare like (possible paralysis of respiratory muscles). MAO inhibitors prolong local anesthesia.
References
- DailyMed. "LIDOCAINE; TETRACAINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- FDA/SPL Indexing Data. "98PI200987: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
- MeSH. "Anti-Arrhythmia Agents". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Partran are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Partran. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported frequency of use
No survey data has been collected yetConsumer reported doses
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
